Navigation Links
Compound might defeat African sleeping sickness, clinical trial beginning this month

One of the most devastating diseases in sub-Saharan Africa almost disappeared in the late 1950s. That disease, African sleeping sickness, or trypanosomiasis, largely succumbed to heroic public health efforts -- including relocating entire villages. But in the past several decades, because of post-colonial turmoil, the catastrophic illness has come back to ravage parts of Angola, the Democratic Republic of the Congo, the Sudan and other countries. In some regions, the tsetse fly-borne infection rivals or exceeds the toll AIDS takes.

Trypanosomiasis is passed from human to human by tsetse fly bites. It produces fever, lymph nodes inflammation, eventual impairment of the brain and nervous system in its late stage and, if not treated, death. The World Health Organization has estimated that more then 300,000 people are infected, and more than 60 million living in the region are at risk.

Now, real hope for a better treatment is on the horizon, based on research conducted in part at the University of North Carolina at Chapel Hill. In Phase II clinical trials, a new oral drug, DB289, demonstrated safety and high effectiveness in subjects with the early stage of sleeping sickness. Scientists are launching a Phase III trial this summer involving for the first time hundreds of patients who will be treated with the drug.

The Bill & Melinda Gates Foundation is supporting the work, which is being led by Dr. Richard R. Tidwell, professor of pathology and laboratory medicine at the UNC School of Medicine.

"This is very exciting time for us and the international consortium we pulled together to develop the first drug made to specifically combat this terrible re-emerging disease," Tidwell said. "The compound DB289 will be the first new drug for early stage (blood stage) African sleeping sickness in 50 years, and the only oral drug that's ever been specifically developed for it."

Oral administration is important for treating the disease which
'"/>

Source:University of North Carolina at Chapel Hill


Page: 1 2 3 4

Related biology news :

1. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
2. Newly Discovered Compound Blocks Known Cancer-Causing Protein
3. Compounds in plastic packaging act as environmental estrogens altering breast genes
4. Compound from Chinese medicine shows promise in head and neck cancer
5. Anti-cancer Compound In Beer Gaining Interest
6. Compound from marine bacteria shows potential as multiple myeloma therapy
7. Compound in dairy products targets diabetes
8. Compound eyes, evolutionary ties
9. Antibiotic might fight HIV-induced neurological problems
10. Newly discovered pathway might help in design of cancer drugs
11. Stem cells electric abilities might help their safe clinical use
Post Your Comments:
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
(Date:7/31/2015)... juillet 2015 La 10e Conférence internationale ... organisée par le BGI du 22 au 25 ... en Chine. La conférence célèbre son ... 2006, l,ICG est devenue l,une des réunions annuelles ... « omiques » et c,est aussi la plus dynamique, la ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... the short end of the stick, in this case the ... at the ends of chromosomes, can be thought of as ... neighboring chromosomes. It is typical for telomeres to ... a new study from Brigham and Women,s Hospital (BWH) suggest ...
... to the way scientists name new plants that took effect ... Latin requirement - a stipulation that descriptions or diagnoses of ... rules make it possible to take full advantage of an ... particular species is indeed new to science: Many studies now ...
... 2012Healthy individuals who carry a gene variation linked to ... their brains that may help explain how the gene ... results of this innovative brain imaging study are described ... Brain Connectivity, a bimonthly peer-reviewed publication from Mary ...
Cached Biology News:The long, err, short of it 2
(Date:9/1/2015)... ... September 01, 2015 , ... GenoCAD, a leading provider ... version of its flagship DNA design platform, which has been enhanced to boost ... numerous genetic parts, which in turn can be recombined using specific sets of ...
(Date:8/31/2015)... Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... million. The orders are for air emission abatement projects in ... is a large order for a municipality in the ... replacing a competitor,s system that failed to meet the customer,s ... solutions," said Derek S. Webb , President and Chief ...
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.17 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has announced ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Middle East & Africa Biomedical ... at a CAGR of 3.26% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
Breaking Biology Technology:GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2
... Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today ... an additional 180 days to regain compliance with NASDAQ,s $1.00 ... on May 3, 2010, CTI was notified by NASDAQ that ... for continued listing and was provided until November 1, 2010 ...
... Nov. 2, 2010 Cadence Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA) has granted marketing approval for ... formulation of acetaminophen to be approved in the United ... to moderate pain, the management of moderate to severe ...
... 2, 2010 Modern Plastics offers SUSTARIN® C ... manufactured by ROCHLING Engineering Plastics. The technology ... sheet and rod are free of centerline or core ... stability for close tolerance parts. A low coefficient of ...
Cached Biology Technology:NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule 2Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 2Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 3Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 4Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 5Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever 6Modern Plastics SUSTARIN® C (Acetal) Product Uses Special Manufacturing Technology to Ensure Every Sheet and Rod Are Free of Centerline or Core Porosity 2
Human Glypican 2 Biotinylated Affinity Purified PAb...
B2-Microgloulin...
... Molecular Imaging's proprietary Focus™ detector technology, while ... the R4. The microPET Focus 120 ... avaiable PET scanner. Focus scanners also ... scinitallor based PETsystems. The combination of ...
...
Biology Products: